Glycogen storage disease type II: Clinical overview

Acta Myologica

Volumn 26, Issue 1, 2007, Pages 42-44

  Di Rocco, Maja ^a   Buzzi, D ^a   Taro M ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Alpha galactosidase; Cardiomyopathy; Myopathy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; LACTATE DEHYDROGENASE;

ARTICLE; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ELECTROCARDIOGRAM; ENZYME ACTIVITY; ENZYME REPLACEMENT; FLUOROMETRY; FOLLOW UP; GENETIC HETEROGENEITY; GLYCOGEN STORAGE DISEASE TYPE 2; HEARING LOSS; HUMAN; LABORATORY TEST; LIFE EXPECTANCY; MASS SPECTROMETRY; MUSCLE FUNCTION; MUSCLE WEAKNESS; NEWBORN SCREENING; ONSET AGE; OUTCOME ASSESSMENT; RESPIRATORY FAILURE; SYMPTOM;

AGE OF ONSET; DIAGNOSIS, DIFFERENTIAL; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS;

EID: 34548611613     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hirschorn R, Reuser AJJ. Glycogen storage disease type II: Acid alpha glucosidase (Acid maltase) deficiency. In: Scriver et al., eds. The Metabolic and Molecular bases of inherited disease. McGraw Hill; 2001. p. 3389-420.
2. Winkel LP, Hagemans MLC, van Doom PA, et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 2005;252:875-84.
3. Ausem MGEM, Berg K, Kroos MA. Glycogen storage disease type II:birth prevalence agrees with predicted genotype frequency. Community Genet 1999;2:91-6.
4. Ausem MGEM, Vierbiest J, Hermans MMP. Frequency of glycogen storage disease type II in the Netherland. Implications for diagnosis and genetic counselling. Eur J Hum Genet 1999;7:713-6.
5. Martiniuk F, Chen A, Mack A. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with this disease. Am J Med Genet 1998;79:69-72.
6. Van den Hout HMP, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from literature. Pediatrics 2003;113:332-40.
7. Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-6.
8. Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2002;2:145-66.
9. Kamphoven JHJ, de Ruiter NMM, Winkel LPF, et al. Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse. Neurobiol Dis 2004;16:14-20.
10. Chien YH, Lee NC, Peng SF, Hwu WL. Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. Pediatr Res 2006;60:349-52.
11. Van den Hout JMP, Kamphoven JHJ, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113:448-57.
12. Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guidelines. Genet Med 2006;8:267-88.
13. Deyfus J, Poenaru L. White blood cells and the diagnosis of alpha glucosidase deficiency. Pediatr Res 1980;14:342-4.
14. Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C. Glycogen storage disease type II: enzymatic screening in dried blood spot on filter paper. Clin Chim Acta 2004;347:97-102.
15. Zhang H, Kallwass H, Young S, Carr C. A comparison of methods for lysosomal acid alpha-glucsidase activity determination from dried blood spots for diagnosis of Pompe disease. Genet Med 2006;8:302-6.